Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol
The drug could be an option for patients who are unable to tolerate statins, or unwilling to take them.
The drug could be an option for patients who are unable to tolerate statins, or unwilling to take them.
A joint SCCT/SCAI panel reviewed many opportunities for CT to enhance procedural planning and foster multidisciplinary care.
In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some areas.
While increasing accessibility is “laudable,” it can come at a cost when patients leave the VA for procedures, Jay Giri says.
The condition, more severe than preeclampsia, should inspire close follow-up for hypertension, heart failure, and stroke.
Access to rehabilitation is a “lifeline” for patients that needs to be protected and preserved to ensure their recovery.
ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the top dose.
Richard A. Shlofmitz, MD St. Francis Hospital Roslyn, NY Johan Bennett, MBBCh, MD, PhD University Ziekenhuis Leuven, Belgium Daniela Benedetto, MD, PhD Tor Vergata University…
In-store opportunities for patients to check in with their health may offer touchpoints to those who don’t regularly seek care.
Patrick O’Gara and Michael Borger give perspectives from the US and Europe, respectively.
Access to rehabilitation is a “lifeline” for patients that needs to be protected and preserved to ensure their recovery.